Ignite Creation Date:
2025-12-24 @ 11:38 PM
Ignite Modification Date:
2026-04-17 @ 1:21 PM
Study NCT ID:
NCT05522556
Status:
AVAILABLE
Last Update Posted:
2025-11-18
First Post:
2022-08-26
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)
Sponsor:
Pfizer
Organization:
Study Overview
Official Title:
None
Status:
AVAILABLE
Status Verified Date:
2025-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Provide pre-approval single patient Expanded Access (compassionate use) of Ritlecitinib for patients.
Detailed Description:
In Expanded Access, treating physicians are the Sponsors. Expanded Access requests from treating physicians may be submitted to www.pfizercares.com. Availability will depend on location and country.
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: